Polar Asset Management Partners Inc. Has $2.40 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Polar Asset Management Partners Inc. boosted its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 86.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 27,900 shares of the company's stock after purchasing an additional 12,900 shares during the quarter. Polar Asset Management Partners Inc.'s holdings in Novo Nordisk A/S were worth $2,400,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in NVO. Nisa Investment Advisors LLC lifted its position in shares of Novo Nordisk A/S by 36.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,500 shares of the company's stock valued at $129,000 after acquiring an additional 400 shares during the period. Linden Thomas Advisory Services LLC lifted its position in shares of Novo Nordisk A/S by 25.7% during the 4th quarter. Linden Thomas Advisory Services LLC now owns 3,555 shares of the company's stock valued at $306,000 after acquiring an additional 726 shares during the period. First Citizens Bank & Trust Co. lifted its position in shares of Novo Nordisk A/S by 7.6% during the 4th quarter. First Citizens Bank & Trust Co. now owns 18,327 shares of the company's stock valued at $1,576,000 after acquiring an additional 1,302 shares during the period. Novare Capital Management LLC lifted its position in shares of Novo Nordisk A/S by 25.6% during the 4th quarter. Novare Capital Management LLC now owns 3,424 shares of the company's stock valued at $295,000 after acquiring an additional 697 shares during the period. Finally, Stablepoint Partners LLC lifted its position in shares of Novo Nordisk A/S by 5.2% during the 4th quarter. Stablepoint Partners LLC now owns 12,068 shares of the company's stock valued at $1,038,000 after acquiring an additional 600 shares during the period. 11.54% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on NVO shares. Dbs Bank downgraded Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. Stifel Nicolaus cut Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Hsbc Global Res raised Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, April 28th. Wall Street Zen raised Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a report on Friday, April 25th. Finally, Morgan Stanley started coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They set an "equal weight" rating for the company. Two analysts have rated the stock with a sell rating, five have given a hold rating, five have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $135.00.

Novo Nordisk A/S Price Performance

NVO traded down $1.80 on Wednesday, reaching $68.64. The stock had a trading volume of 7,844,001 shares, compared to its average volume of 6,730,361. Novo Nordisk A/S has a fifty-two week low of $57.00 and a fifty-two week high of $148.15. The firm has a 50-day moving average of $65.91 and a 200-day moving average of $82.38. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $308.02 billion, a price-to-earnings ratio of 20.86, a price-to-earnings-growth ratio of 0.90 and a beta of 0.65.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. The business had revenue of $11.87 billion during the quarter. As a group, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.